Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

CEO

Mahesh V. Patel

Employees

Country

United States

ISIN

US53630X1046

WKN

000A3EBZD

Listings

0 Comments

Share your thoughts

FAQ

What is Lipocine stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Lipocine stocks are traded under the ticker 2VT.STU.

When is the next Lipocine earnings date?▼

Lipocine is going to release the next earnings report on November 11, 2026.

What were Lipocine earnings last quarter?▼

2VT.STU earnings for the last quarter are -0.28 EUR per share, whereas the estimation was -0.35 EUR resulting in a +20% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Lipocine revenue for the last year?▼

Lipocine revenue for the last year amounts to 1.69M EUR.

What is Lipocine net income for the last year?▼

2VT.STU net income for the last year is -8.33M EUR.

How many employees does Lipocine have?▼

As of September 06, 2026, the company has 14 employees.

In which sector is Lipocine located?▼

Lipocine operates in the Health & Wellness sector.

When did Lipocine complete a stock split?▼

The last stock split for Lipocine was on May 12, 2023 with a ratio of 1:17.

Where is Lipocine headquartered?▼

Lipocine is headquartered in SALT LAKE CITY, United States.